Our study results suggest that drugs targeting Nrf2-HMOX1 might serve as a viable approach for utilizing ferroptosis to kill resistant lung cancer cells via a specific inhibitor of Nrf2. This evidence concerns the gene HMOX1 and lung carcinoma.